Download PDF
Horm Metab Res 2019; 51(07): 437-442
DOI: 10.1055/a-0918-8340
Review

Paragangliomas in Carney–Stratakis Syndrome

Arushi Khurana
1   VCU Massey Cancer Center - Hematology Oncology, Richmond, Virginia, USA
,
Lin Mei
1   VCU Massey Cancer Center - Hematology Oncology, Richmond, Virginia, USA
,
Anthony C. Faber
2   Virginia Commonwealth University - Philips Institute for Oral Health Research, Richmond, Virginia, USA
,
Steven C. Smith
3   Virginia Commonwealth University - Pathology, Richmond, Virginia, USA
,
Sosipatros A. Boikos
1   VCU Massey Cancer Center - Hematology Oncology, Richmond, Virginia, USA
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Carney-Stratakis Syndrome (CSS) comprises of paragangliomas (PGLs) and gastrointestinal stromal tumors (GISTs). Several of its features overlap with Carney Triad (CT) - PGLs, GISTs, and pulmonary chondromas. CSS has autosomal dominant inheritance, incomplete penetrance, and greater relative frequency of PGL over GISTs. The PGLs in CSS are multicentric and GISTs are multifocal in all the patients, suggesting an inherited susceptibility and associating the two manifestations. In this review, we highlight the clinical, pathological, and molecular characteristics of CSS, along with its diagnostic and therapeutic implications.

Key words

Carney–Stratakis syndrome - paragangliomas - GIST - pheochromocytomas


Publication History

Received: 11 November 2018

Accepted: 07 May 2019

Article published online:
07 June 2019

Georg Thieme Verlag
Rüdigerstraße 14,70469 Stuttgart, Germany

 

  • References

  • 1 Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: A new syndrome distinct from the Carney triad. Am J Med Genet 2002; 108: 132-139
    Google Scholar
  • 2 Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: Diagnosis, genetics, management, and treatment. Curr Probl Cancer 2014; 38: 7-41
    Google Scholar
  • 3 Drovdlic CM, Myers EN, Peters JA. et al. Proportion of heritable paraganglioma cases and associated clinical characteristics. Laryngoscope 2001; 111: 1822-1827
    Google Scholar
  • 4 Sobol SM, Dailey JC. Familial multiple cervical paragangliomas: Report of a Kindred and Review of the Literature. Otolaryngol Neck Surg 1990; 102: 382-390
    Google Scholar
  • 5 Pasini B, McWhinney SR, Bei T. et al. Clinical and molecular genetics of patients with the Carney–Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC and SDHD. Eur J Hum Genet 2008; 16: 79-88
    Google Scholar
  • 6 McWhinney SR, Pasini B, Stratakis CA. et al. Familial gastrointestinal stromal tumors and germ-line mutations. N Engl J Med 2007; 357: 1054-1056
    Google Scholar
  • 7 Hirota S, Isozaki K, Moriyama Y. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580
    Google Scholar
  • 8 Huss S, Künstlinger H, Wardelmann E. et al. A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del). Mod Pathol 2013; 26: 1004-1012
    Google Scholar
  • 9 Rossi S, Gasparotto D, Miceli R. et al. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of Imatinib-naive localized GIST. Am J Surg Pathol 2015; 39: 922-930
    Google Scholar
  • 10 Janeway KA, Kim SY, Lodish M. et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011; 108: 314-318
    Google Scholar
  • 11 Killian JK, Kim SY, Miettinen M. et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov 2013; 3: 648-657
    Google Scholar
  • 12 Boikos SA, Stratakis CA. The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations. Endocrine 2014; 47: 401-408
    Google Scholar
  • 13 Dahia PLM. Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic heterogeneity. Nat Rev Cancer 2014; 14: 108-119
    Google Scholar
  • 14 Fishbein L, Leshchiner I, Walter V. et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 2017; 31: 181-193
    Google Scholar
  • 15 Crona J, Taïeb D, Pacak K. New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification. Endocr Rev 2017; 38: 489-515
    Google Scholar
  • 16 Astuti D, Latif F, Dallol A. et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001; 69: 49-54
    Google Scholar
  • 17 Astuti D, Douglas F, Lennard TW. et al. Germline SDHD mutation in familial phaeochromocytoma. Lancet 2001; 357: 1181-1182
    Google Scholar
  • 18 Baysal BE, Ferrell RE, Willett-Brozick JE. et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287: 848-851
    Google Scholar
  • 19 Udager AM, Magers MJ, Goerke DM. et al. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes. Hum Pathol 2018; 71: 47-54
    Google Scholar
  • 20 Clark GR, Sciacovelli M, Gaude E. et al. Germline FH mutations presenting with pheochromocytoma. J Clin Endocrinol Metab 2014; 99: E2046-E2050
    Google Scholar
  • 21 Hoekstra AS, Bayley J-P. The role of complex II in disease. Biochim Biophys Acta Bioenerg 2013; 1827: 543-551
    Google Scholar
  • 22 Bardella C, Pollard PJ, Tomlinson I. SDH mutations in cancer. Biochim Biophys Acta Bioenerg 2011; 1807: 1432-1443
    Google Scholar
  • 23 Scheffler IE. Molecular genetics of succinate:quinone oxidoreductase in eukaryotes. Prog Nucleic Acid Res Mol Biol 1998; 60: 267-315
    Google Scholar
  • 24 Gill AJ. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology 2012; 44: 285-292
    Google Scholar
  • 25 Favier J, Amar L, Gimenez-Roqueplo A-P. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol 2015; 11: 101-111
    Google Scholar
  • 26 Mason EF, Hornick JL. Succinate dehydrogenase deficiency is associated with decreased 5-hydroxymethylcytosine production in gastrointestinal stromal tumors: implications for mechanisms of tumorigenesis. Mod Pathol 2013; 26: 1492-1497
    Google Scholar
  • 27 Selak MA, Armour SM, MacKenzie ED. et al. Succinate links TCA cycle dysfunction to oncogenesis by Inhibiting HIF-α prolyl hydroxylase. Cancer Cell 2005; 7: 77-85. Available from http://www.ncbi.nlm.nih.gov/pubmed/15652751
    Google Scholar
  • 28 Pantaleo MA, Nannini M, Astolfi A. et al. A Distinct Pediatric-type Gastrointestinal Stromal Tumor in Adults. Am J Surg Pathol 2011; 35: 1750-1752
    Google Scholar
  • 29 Pantaleo MA, Astolfi A, Indio V. et al. SDHA Loss-of-Function Mutations in KIT-PDGFRA Wild-Type Gastrointestinal Stromal Tumors Identified by Massively Parallel Sequencing. J Natl Cancer Inst 2011; 103: 983-987
    Google Scholar
  • 30 Wagner AJ, Remillard SP, Zhang Y-X. et al. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod Pathol 2013; 26: 289-294
    Google Scholar
  • 31 Gill AJ, Benn DE, Chou A. et al. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol 2010; 41: 805-814
    Google Scholar
  • 32 van Nederveen FH, Gaal J, Favier J. et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009; 10: 764-771
    Google Scholar
  • 33 Barletta JA, Hornick JL. Succinate Dehydrogenase-deficient Tumors. Adv Anat Pathol 2012; 19: 193-203
    Google Scholar
  • 34 Dwight T, Benn DE, Clarkson A. et al. Loss of SDHA Expression Identifies SDHA Mutations in Succinate Dehydrogenase–deficient Gastrointestinal Stromal Tumors. Am J Surg Pathol 2013; 37: 226-233
    Google Scholar
  • 35 Dwight T, Mann K, Benn DE. et al. Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. J Clin Endocrinol Metab 2013; 98: E1103-E1108
    Google Scholar
  • 36 Boikos SA, Pappo AS, Killian JK. et al. Molecular Subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors. JAMA. Oncol 2016; 2: 922
    Google Scholar
  • 37 Weldon CB, Madenci AL, Boikos SA. et al. Surgical management of wild-type gastrointestinal stromal tumors: A Report from the National Institutes of Health Pediatric and Wildtype GIST Clinic. J Clin Oncol 2017; 35: 523-528
    Google Scholar
  • 38 Zhang L, Smyrk TC, Young WF. et al. Gastric stromal tumors in carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: Findings in 104 cases. Am J Surg Pathol 2010; 34: 53-64
    Google Scholar
  • 39 Miettinen M, Wang Z-F, Sarlomo-Rikala M. et al. Succinate Dehydrogenase-Deficient GISTs. Am J Surg Pathol 2011; 35: 1712-1721
    Google Scholar
  • 40 Wada R, Arai H, Kure S. et al. “Wild type” GIST: Clinicopathological features and clinical practice. Pathol Int 2016; 66: 431-437
    Google Scholar
  • 41 Miettinen M, Killian JK, Wang Z-F. et al. Immunohistochemical Loss of Succinate Dehydrogenase Subunit A (SDHA) in Gastrointestinal Stromal Tumors (GISTs) Signals SDHA Germline Mutation. Am J Surg Pathol 2013; 37: 234-240
    Google Scholar
  • 42 Gaal J, Stratakis CA, Carney JA. et al. SDHB immunohistochemistry: A useful tool in the diagnosis of Carney–Stratakis and Carney triad gastrointestinal stromal tumors. Mod Pathol 2011; 24: 147-1510271
    Google Scholar
  • 43 Mason EF, Hornick JL. Conventional risk stratification fails to predict progression of succinate dehydrogenase–deficient gastrointestinal stromal tumors. Am J Surg Pathol 2016; 40: 1616-1621
    Google Scholar
  • 44 Eisenhofer G, Lenders JWM, Timmers H. et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem 2011; 57: 411-420
    Google Scholar
  • 45 Timmers HJLM, Kozupa A, Eisenhofer G. et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B -associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 2007; 92: 779-786
    Google Scholar
  • 46 Schovanek J, Martucci V, Wesley R. et al. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. BMC Cancer 2014; 14: 523
    Google Scholar
  • 47 Turkova H, Prodanov T, Maly M. et al. Characteristics and outcomes of metastatic SDHB and Sporadic Pheochromocytoma/Paraganglioma: A National Institutes of Health study. Endocr Pract 2016; 22: 302-314
    Google Scholar
  • 48 Janssen I, Chen CC, Taieb D. et al. 68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI. J Nucl Med 2016; 57: 186-191
    Google Scholar
  • 49 Naji M, Zhao C, Welsh SJ. et al. 68Ga-DOTA-TATE PET vs. 123I-MIBG in Identifying Malignant Neural Crest Tumours. Mol Imaging Biol 2011; 13: 769-775
    Google Scholar
  • 50 Gimenez-Roqueplo A-P, Caumont-Prim A, Houzard C. et al. Imaging Work-Up for Screening of Paraganglioma and Pheochromocytoma in SDHx Mutation Carriers: A Multicenter Prospective Study from the PGL.EVA Investigators. J Clin Endocrinol Metab 2013; 98: E162-E173
    Google Scholar
  • 51 Elston MS, Meyer-Rochow GY, Conaglen HM. et al. Increased SSTR2A and SSTR3 expression in succinate dehydrogenase–deficient pheochromocytomas and paragangliomas. Hum Pathol 2015; 46: 390-396
    Google Scholar
  • 52 Amar L, Servais A, Gimenez-Roqueplo A-P. et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005; 90: 2110-2116
    Google Scholar
  • 53 Amar L, Lussey-Lepoutre C, Lenders JWM. et al. Management of endocrine disease: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis. Eur J Endocrinol 2016; 175: R135-R145
    Google Scholar
  • 54 Pacak K. Preoperative Management of the Pheochromocytoma Patient. J Clin Endocrinol Metab 2007; 92: 4069-4079
    Google Scholar
  • 55 Plouin P-F, Duclos J-M, Soppelsa F. et al. Factors Associated with Perioperative Morbidity and Mortality in Patients with Pheochromocytoma: Analysis of 165 Operations at a Single Center. J Clin Endocrinol Metab 2001; 86: 1480-1486
    Google Scholar
  • 56 Goldstein RE, O’Neill JA, Holcomb GW. et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999; 229: 755-764 discussion 764–766
    Google Scholar
  • 57 Krempf M, Lumbroso J, Mornex R. et al. Treatment of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: A French multicenter study. J Nucl Biol Med 1991; 35: 284-287
    Google Scholar
  • 58 Loh KC, Fitzgerald PA, Matthay KK. et al. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients. J Endocrinol Invest 1997; 20: 648-658
    Google Scholar
  • 59 Huang H, Abraham J, Hung E. et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine. Cancer 2008; 113: 2020-2028
    Google Scholar
  • 60 Niemeijer ND, Alblas G, van Hulsteijn LT. et al. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: Systematic review and meta-analysis. Clin Endocrinol (Oxf) 2014; 81: 642-651
    Google Scholar
  • 61 Asai S, Katabami T, Tsuiki M. et al. Controlling tumor progression with cyclophosphamide, vincristine, and dacarbazine treatment improves survival in patients with metastatic and unresectable malignant pheochromocytomas/paragangliomas. Horm Cancer 2017; 8: 108-118
    Google Scholar
  • 62 Tanabe A, Naruse M, Nomura K. et al. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer 2013; 4: 103-110
    Google Scholar
  • 63 Hadoux J, Favier J. Scoazec J-Yet al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer 2014; 135: 2711-2720
    Google Scholar
  • 64 Ayala-Ramirez M, Chougnet CN, Habra MA. et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab 2012; 97: 4040-4050
    Google Scholar
  • 65 Jasim S, Suman VJ, Jimenez C. et al. Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma. Endocrine 2017; 57: 220-225
    Google Scholar
  • 66 Jasperson KW, Kohlmann W, Gammon A. et al. Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families. Fam Cancer 2014; 13: 257-265
    Google Scholar
  • 67 Aufforth RD, Ramakant P, Sadowski SM. et al. Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome. J Clin Endocrinol Metab 2015; 100: 4498-4504
    Google Scholar
  • 68 Williamson SR, Eble JN, Amin MB. et al. Succinate dehydrogenase-deficient renal cell carcinoma: Detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. Mod Pathol 2015; 28: 80-94
    Google Scholar
  • 69 Gupta S, Zhang J, Milosevic D. et al. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel–Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127). Endocr Pathol 2017; 28: 253-268
    Google Scholar
  • 70 Mei L, Smith SC, Faber AC. et al. Gastrointestinal stromal tumors: The GIST of precision medicine. trends. Cancer 2018; 4: 74-91
    Google Scholar
  • 71 Zhuang Z, Yang C, Lorenzo F. et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 2012; 367: 922-930
    Google Scholar